Azitra Inc (AZTR)

$0.31 +0.02 (5.52%)
Market Cap 3.19M
Revenue (ttm) 10,000.00
Net Income (ttm) -8.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,700.00%
Debt to Equity Ratio 0.00
Volume 440,500
Avg Vol 3,250,886
Day's Range N/A - N/A
Shares Out 10.74M
Stochastic %K 39%
Beta -1.65
Analysts Strong Sell
Price Target $2.70

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular ras...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 646 6446
Address:
21 Business Park Drive, Branford, United States
JohnTrack
JohnTrack Dec. 23 at 11:41 PM
$AZTR tracking reactions to news...
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 9:27 PM
$AZTR new news... https://www.rapidticker.com/news/aztr-sec-filing-c05b2f
0 · Reply
pbacher
pbacher Dec. 23 at 9:12 PM
$AZTR At the Special Meeting, we will consider and act on the following items of business: 1. To approve, for purposes of complying with NYSE American Company Guide Section 713(a) and Section 713(b), the issuance of more than 19.99% of the Company’s issued and outstanding shares of common stock, comprised of shares of common stock underlying warrants, pursuant to the securities purchase agreement with Alumni Capital LP, dated November 24, 2025 (the “Stock Issuance Proposal”); and 2. To adjourn the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes in favor of the foregoing proposal (the “Adjournment
0 · Reply
pbacher
pbacher Dec. 23 at 9:11 PM
$AZTR You are cordially invited to attend a Special Meeting of Stockholders (which we refer to as the “Special Meeting”) of Azitra, Inc., a Delaware corporation (which we refer to as “Azitra,” “we,” “us,” “our,” or the “Company”), to be held on Friday, February 6, 2026 at 11:00 a.m. ET.
0 · Reply
pbacher
pbacher Dec. 22 at 10:33 PM
$AZTR many 4g filings published
1 · Reply
Yousef490
Yousef490 Dec. 20 at 5:05 PM
$AZTR Azitra has received a Notice of Allowance for U.S. Patent Application No. 18/234,588 titled “Compositions and Methods for Treatment of Netherton Syndrome with Lekti Expressing Recombinant Microbes.”
1 · Reply
pbacher
pbacher Dec. 20 at 8:40 AM
$AZTR 13g
1 · Reply
pbacher
pbacher Dec. 19 at 1:03 PM
$AZTR haha, plus 12 percent to minus 8 percent in seconds =D What a bullshit
2 · Reply
pbacher
pbacher Dec. 18 at 9:03 PM
$AZTR wow, not even good news help anymore -.-
0 · Reply
pbacher
pbacher Dec. 18 at 5:36 PM
$AZTR this stock is insane =D
0 · Reply
Latest News on AZTR
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Dec 17, 2025, 4:10 PM EST - 7 days ago

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Nov 24, 2025, 9:00 AM EST - 4 weeks ago

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Nov 12, 2025, 5:15 PM EST - 6 weeks ago

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Nov 7, 2025, 6:00 AM EST - 6 weeks ago

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Oct 20, 2025, 8:02 AM EDT - 2 months ago

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Azitra Receives Notice of Non-Compliance from NYSE American

Oct 3, 2025, 4:45 PM EDT - 2 months ago

Azitra Receives Notice of Non-Compliance from NYSE American

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:10 AM EDT - 4 months ago

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Aug 27, 2025, 8:10 AM EDT - 4 months ago

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

Aug 22, 2025, 6:01 AM EDT - 4 months ago

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

IVV SPXL SPY SSO UPRO VOO ZM

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Aug 11, 2025, 5:00 PM EDT - 4 months ago

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Azitra, Inc. Announces Reverse Stock Split

Aug 11, 2025, 4:15 PM EDT - 4 months ago

Azitra, Inc. Announces Reverse Stock Split

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 17, 2025, 8:02 AM EDT - 6 months ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Jun 10, 2025, 8:33 AM EDT - 7 months ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 28, 2025, 8:33 AM EDT - 7 months ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 14, 2025, 4:05 PM EDT - 8 months ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

May 13, 2025, 5:06 PM EDT - 8 months ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 25, 2025, 8:33 AM EDT - 8 months ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Apr 24, 2025, 4:05 PM EDT - 8 months ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Azitra to Present at Microbiome Times Partnering Forum

Mar 12, 2025, 8:33 AM EDT - 10 months ago

Azitra to Present at Microbiome Times Partnering Forum

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:30 AM EST - 10 months ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 4, 2025, 2:20 PM EST - 11 months ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Feb 3, 2025, 9:05 AM EST - 11 months ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Azitra, Inc. to Present at The Microcap Conference

Jan 27, 2025, 4:05 PM EST - 11 months ago

Azitra, Inc. to Present at The Microcap Conference

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 15, 2025, 8:30 AM EST - 1 year ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Azitra Announces Proposed Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 1 year ago

Azitra Announces Proposed Public Offering of Common Stock

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Nov 12, 2024, 5:05 PM EST - 1 year ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Azitra to Present at BIO-Europe 2024

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 11, 2024, 9:00 AM EDT - 1 year ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 18, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 20, 2024, 4:15 PM EDT - 1 year ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 6:23 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Jul 25, 2024, 5:57 PM EDT - 1 year ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

Jul 25, 2024, 1:54 PM EDT - 1 year ago

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

HAL

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

Jul 25, 2024, 1:13 PM EDT - 1 year ago

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

HAL

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Jul 23, 2024, 9:20 PM EDT - 1 year ago

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

May 31, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

May 17, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

May 10, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

May 9, 2024, 5:00 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 15, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Azitra, Inc. Announces Closing of Public Offering

Feb 16, 2024, 4:05 PM EST - 2 years ago

Azitra, Inc. Announces Closing of Public Offering

Azitra, Inc. Announces Pricing of Public Offering

Feb 13, 2024, 10:09 PM EST - 2 years ago

Azitra, Inc. Announces Pricing of Public Offering

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Jan 16, 2024, 9:00 AM EST - 2 years ago

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

JohnTrack
JohnTrack Dec. 23 at 11:41 PM
$AZTR tracking reactions to news...
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 9:27 PM
$AZTR new news... https://www.rapidticker.com/news/aztr-sec-filing-c05b2f
0 · Reply
pbacher
pbacher Dec. 23 at 9:12 PM
$AZTR At the Special Meeting, we will consider and act on the following items of business: 1. To approve, for purposes of complying with NYSE American Company Guide Section 713(a) and Section 713(b), the issuance of more than 19.99% of the Company’s issued and outstanding shares of common stock, comprised of shares of common stock underlying warrants, pursuant to the securities purchase agreement with Alumni Capital LP, dated November 24, 2025 (the “Stock Issuance Proposal”); and 2. To adjourn the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes in favor of the foregoing proposal (the “Adjournment
0 · Reply
pbacher
pbacher Dec. 23 at 9:11 PM
$AZTR You are cordially invited to attend a Special Meeting of Stockholders (which we refer to as the “Special Meeting”) of Azitra, Inc., a Delaware corporation (which we refer to as “Azitra,” “we,” “us,” “our,” or the “Company”), to be held on Friday, February 6, 2026 at 11:00 a.m. ET.
0 · Reply
pbacher
pbacher Dec. 22 at 10:33 PM
$AZTR many 4g filings published
1 · Reply
Yousef490
Yousef490 Dec. 20 at 5:05 PM
$AZTR Azitra has received a Notice of Allowance for U.S. Patent Application No. 18/234,588 titled “Compositions and Methods for Treatment of Netherton Syndrome with Lekti Expressing Recombinant Microbes.”
1 · Reply
pbacher
pbacher Dec. 20 at 8:40 AM
$AZTR 13g
1 · Reply
pbacher
pbacher Dec. 19 at 1:03 PM
$AZTR haha, plus 12 percent to minus 8 percent in seconds =D What a bullshit
2 · Reply
pbacher
pbacher Dec. 18 at 9:03 PM
$AZTR wow, not even good news help anymore -.-
0 · Reply
pbacher
pbacher Dec. 18 at 5:36 PM
$AZTR this stock is insane =D
0 · Reply
JohnTrack
JohnTrack Dec. 17 at 10:06 PM
$AZTR plan accepted by AMEX https://www.rapidticker.com/news/aztr-sec-filing-16356d
0 · Reply
Bulltrader988
Bulltrader988 Dec. 17 at 9:19 PM
$AZTR "...Azitra must regain compliance with the continued listing standards by April 1, 2027. If Azitra is not in compliance with the continued listing standards by April 1, 2027, or if Azitra does not make progress consistent with the Plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate.. Azitra will continue its listing on NYSE American during the plan period and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan until it has regained compliance. Azitra is assessing and exploring multiple funding avenues and is committed to achieving compliance with the Exchange's requirements.." 👃👀 https://www.stocktitan.net/news/AZTR/azitra-receives-notice-of-acceptance-of-the-listing-standards-s00aaaxieinv.html
1 · Reply
Bulltrader988
Bulltrader988 Dec. 17 at 9:19 PM
$AZTR "..today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra received a letter from the NYSE American stating that Azitra is not in compliance with the minimum stockholders' equity requirement of Section 1003(a)(ii) of the Company Guide requiring stockholders' equity of $4.0 million or more if Azitra has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years.." 👃👀 https://www.stocktitan.net/news/AZTR/azitra-receives-notice-of-acceptance-of-the-listing-standards-s00aaaxieinv.html
0 · Reply
pbacher
pbacher Dec. 17 at 9:16 PM
$AZTR Azitra Receives NYSE American Approval Of Compliance Plan, Must Regain Listing Standards By April 1, 2027
0 · Reply
pbacher
pbacher Dec. 17 at 9:12 PM
$AZTR Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
0 · Reply
dln101
dln101 Dec. 17 at 2:26 PM
$VYNE peeny bios time to bounce back 🔥 next in line 👉 $AZTR $ADIL 💪👌📈
0 · Reply
pbacher
pbacher Dec. 17 at 1:35 PM
$AZTR What a bullshit
0 · Reply
pbacher
pbacher Dec. 17 at 12:49 PM
$AZTR this shorts availability is so weird
0 · Reply
dln101
dln101 Dec. 16 at 8:50 PM
$AZTR $ADIL which of these pennies will spike like $VMAR 🤔
0 · Reply
TroyRayRoberson
TroyRayRoberson Dec. 16 at 2:39 PM
$AZTR bought dip @ 0.2935 loaded up
0 · Reply
pbacher
pbacher Dec. 16 at 2:06 PM
$AZTR now the drop makes sense -.- what a bullshit Up to 38,944,662 Shares of Common Stock Up to 4,151,741 Shares of Common Stock Underlying the November Pre-Funded Warrants Up to 4,687,500 Shares of Common Stock Underlying the November Common Stock Purchase Warrants Up to 187,500 Shares of Common Stock Underlying the Placement Agent Warrants Up to 3,840,890 Shares of Common Stock Underlying the ELOC Warrants
0 · Reply
pbacher
pbacher Dec. 15 at 7:45 PM
$AZTR and here it is our new atl. Unbelievable. Un fuckin believable
1 · Reply